$6.57
-0.13(-1.94%)
Mkt Cap $417M
$4.90
$7.23
52-Week Range
At a Glance
AI-generatedAura Biosciences deepened its operating losses in FY2025 amid continued investment in late-stage clinical development, with cash outflows rising and free cash flow deteriorating, reflecting the financial intensity of advancing bel-sar through pivotal trials.
8-K
Aura Biosciences reported Q4 and FY 2025 financial results, highlighting accelerated Phase 3 enrollment with topline data expected in 2H 2027 and a cash runway extending into Q1 2027.$417M
Market Cap
—
Revenue
-$103M
Net Income
Employees106
Fundamentals
How The Business Makes Money
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001501796
ISINUS05153U1079
CUSIP05153U107
Phone617 500 8864
Address85 Bolton Street, Boston, MA, 02140, US
SEC EDGAR